February 27, 2025

The Business Group submitted a statement to the House Energy & Commerce Subcommittee on Health in regards to its February 26, 2025 hearing, "An Examination of How Reining in PBMs Will Drive Competition and Lower Costs for Patients." In our submission, the Business Group explained the importance of transparency in combating high prescription drug costs while also emphasizing why certain policies, such as the addition of new civil monetary penalties under ERISA, would hinder plan sponsors and lead to higher costs and reduced flexibility.

Business Group on Health Submits Statement on Price Transparency and Pharmacy Benefit Manager Reforms

More Topics

Resource Employee Retirement Income Security Act (ERISA) Transparency Vendor Management & Accountability